|
A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients Clinical research trials and A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients. A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients clinical trial. Participants frequently get the best healthcare available for their A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients  A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To compare the virologic response between abacavir (ABC, 1592U89) regimens (drug vs. placebo) and between the 2 dosing regimens (BID vs. TID) with respect to the proportion of patients with plasma HIV RNA levels below the limit of detection [AS PER AMENDMENT 8/27/97: < 500 copies/ml at week 16]. To evaluate the safety and tolerance of the study arms. [AS PER AMENDMENT 3/10/99: During the extension period, compare the time to detectable viremia (2 consecutive plasma HIV RNA levels greater than or equal to 500 copies/ml) between ABC and placebo.] Therapeutically, there is a need to explore potent alternative therapy for patients who have received, or are currently receiving, a double nucleoside analog combination including lamivudine (3TC), a regimen that was proven to be clinically inferior to indinavir (IDV) when combined with zidovudine/3TC in study ACTG 320. In order to produce and maintain a maximal antiviral response, all patients in this study will receive 2 or 3 potent, new agents; ABC, a nucleoside analog, EFV, a non-nucleoside reverse transcriptase inhibitor (NNRTI), and IDV, a protease inhibitor. Virologically, the major question this protocol seeks to answer is how prior 3TC exposure in a dual nucleoside regimen influences the response to subsequent treatment. It is unclear whether it is best to add a protease inhibitor either 1) an NNRTI at 1 of 2 doses, or 2) an NNRTI at 1 of 2 doses plus a new nucleoside analog to achieve plasma HIV RNA levels that are below the limits of detection.
Details: Therapeutically, there is a need to explore potent alternative therapy for patients who have received, or are currently receiving, a double nucleoside analog combination including lamivudine (3TC), a regimen that was proven to be clinically inferior to indinavir (IDV) when combined with zidovudine/3TC in study ACTG 320. In order to produce and maintain a maximal antiviral response, all patients in this study will receive 2 or 3 potent, new agents; ABC, a nucleoside analog, EFV, a non-nucleoside reverse transcriptase inhibitor (NNRTI), and IDV, a protease inhibitor. Virologically, the major question this protocol seeks to answer is how prior 3TC exposure in a dual nucleoside regimen influences the response to subsequent treatment. It is unclear whether it is best to add a protease inhibitor either 1) an NNRTI at 1 of 2 doses, or 2) an NNRTI at 1 of 2 doses plus a new nucleoside analog to achieve plasma HIV RNA levels that are below the limits of detection. Prior to randomization, patients are stratified by CD4 cell count (cells/mm3): less than or equal to 50 versus greater than 50 and by ACTG 320 participation: enrolled versus not enrolled. Patients with greater than 50 CD4 cells/mm3 are randomized to 1 of 4 treatment arms (Arms I, II, III, or IV) and patients with less than or equal to 50 CD4 cells/mm3 are randomized to 1 of 2 treatment arms (Arms I and II). All patients will be followed for 48 weeks beyond the enrollment of the last patient. The regimens for the treatment arms are as follows: Arm I - indinavir (IDV) plus EFV plus ABC placebo bid, Arm II - IDV (higher dose) plus EFV (lower dose) plus ABC, Arm III - IDV plus EFV plus ABC placebo, and Arm IV - IDV (higher dose) plus EFV (lower dose) plus ABC. If 15 week data indicates this is a reasonable dosing regimen, the sample size in Arms III and IV will be expanded to include additional patients with a CD4 count greater than 50 cells/mm3 and allow for equal enrollment across all 4 treatment arms. Those patients who roll over from ACTG 320 will be assigned to receive open-label treatment on Arm II and evaluated independently of the 4 treatment arms listed above. [AS PER AMENDMENT 8/27/97: Patients with 2 consecutive HIV RNA measurements at least 500 copies/ml at week 16 or anytime thereafter are given the option to receive open-label treatment with IDV plus EFV plus ABC, or to seek the best available therapy outside of the study. NOTE: Patients who choose the open-label combination may take other prescribed nucleoside analogs provided outside the study.] [AS PER AMENDMENT 12/17/97: It is strongly recommended that patients who reach a confirmed endpoint and elect to receive open-label therapy consider adding additional approved (and novel, if possible) antiretroviral agents to their open-label regimen.] [AS PER AMENDMENT 1/12/98: Patients who choose the open-label combination may receive other approved antiretrovirals obtained outside the study provided the ACTG 368 team approves the combination.] [AS PER AMENDMENT 8/7/98: Subjects will take study medications for a maximum of 96 weeks, depending on their time of study enrollment.] [AS PER AMENDMENT 3/10/99: A 24-week extension, which will end July 30, 1999, has been added to the study. The extension applies to subjects currently on blinded Step 1 treatment, on open-labeled Step 2, or on study but off treatment. Subjects are to be unblinded in their study treatment and followed for the remainder of the extension. Subjects continue on their current study drug schedule. Subjects on blinded IDV plus EFV who, upon unblinding (not failure) decide to add prescription ABC to their regimen, will be considered off study treatment and will be followed for the duration of the extension; those already registered on Step 2 will continue their Step 2 therapy. Any subject who does not wish to continue on the study extension will be unblinded to their original randomized regimen. Subjects who experience virologic failure during the extension should seek best available treatment following current recommendations to use as many approved, novel antiretroviral agents as possible. The new drug regimen may incorporate any or all of the study drugs.]
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Chemoprophylaxis for Pneumocystis carinii pneumonia is required for all patients who have a CD4 cell count <= 200 cells/mm3. - Topical and/or oral antifungal agents are permitted except for oral ketoconazole. - Treatment, maintenance or chemoprophylaxis with approved agents for opportunistic infections as clinically indicated, except for rifabutin. - All antibiotics as clinically indicated. - Systemic corticosteroid use for <= 21 days for acute problems is permitted as medically indicated; chronic systemic corticosteroid use is not permitted, unless it is within physiologic replacement levels. - Recombinant erythropoietin and granulocyte colony-stimulating factor are permitted as medically indicated. - Regularly prescribed medications such as antipyretics, analgesics, allergy medications (except for terfenadine (Seldane) and astemizole (Hismanal)), antidepressants, sleep medications, oral contraceptives, megestrol acetate, testosterone or any other medications are permitted as medically indicated. NOTE: - Due to the possibility that EFV or ABC may alter the effectiveness of oral contraceptives or depo-progesterone, oral contraceptives or depo-progesterone must not be used as the sole form of birth control. [AS PER AMENDMENT 8/7/98: adequate birth control is hormonal plus barrier method or two barrier methods]. - Alternative therapies such as vitamins, acupuncture, and visualization techniques will be permitted. Herbal medications should be avoided. Patients should report the use of these therapies; alternative therapies will be recorded. [AS PER AMENDMENT 8/7/98: Due to the likelihood of IDV increasing the concentrations of sildenafil (Viagra) when coadministered, it is suggested that subjects who use viagra take the lowest dose (25 mg, i.e., half the typical dose).] Both NIAID ACTG 320 participants and non-ACTG 320 patients must have: - Documented HIV-1 infection. - Written informed consent from parent or legal guardian for those patients < 18 years old. Non-ACTG 320 patients must have: - Documented CD4 cell count <= 200 cells/mm3 at the time of initiation of ZDV (or d4T) plus 3TC therapy [AS PER AMENDMENT 12/17/97: - Documented CD4 cell count <= 250 cells/mm3 within 3 months of initiation of ZDV (or d4T) plus 3TC therapy]. Prior Medication: Required: For ACTG 320 patients: - Patients must have participated in ACTG 320 with original randomization to the double-nucleoside combination arm, and maintenance of that treatment (on-study/on-treatment in ACTG 320) until enrollment into ACTG 368. For non-ACTG 320 patients: - Greater than or equal to 3 months [2 months AS PER AMENDMENT 12/17/97] of therapy with ZDV (or d4T) + 3TC and receiving ZDV (or d4T) + 3TC at the time of entry. Exclusion Criteria Co-existing Condition: Non-ACTG 320 patients with the following symptoms and conditions are excluded: Malignancy that requires systemic therapy other than minimal Kaposi's sarcoma. NOTE: - Minimal Kaposi's sarcoma, defined as <= 5 cutaneous lesions and no visceral disease or tumor-associated edema, allowed, provided systemic therapy not required. Non-ACTG 320 patients with the following prior conditions or symptoms are excluded: - Unexplained temperature > 38.5 degrees C for 7 consecutive days. - Chronic diarrhea defined as > 3 liquid stools per day persisting for 15 days, within 30 days prior to entry. - Proven or suspected acute hepatitis within 30 days prior to entry, even if AST (SGOT) and ALT (SGPT) are <= 5 X ULN. Concurrent Medication: Excluded: - All antiretroviral therapies other then study medications. - Rifabutin and rifampin. - Investigational drugs without specific approval from the protocol chair. - Systemic cytotoxic chemotherapy. - Oral ketoconazole (Nizoral), terfenadine (Seldane), astemizole (Hismanal), cisapride (Propulsid), triazolam (Halcion), and midazolam (Versed). - Caution should be taken in the consumption of alcoholic beverages with study medications. - Itraconazole. Prior Medication: Excluded: For ACTG 320 patients: - Those who opted to receive open-label IDV while on ACTG 320, or if they switched to open label IDV during the study. For non-ACTG 320 patients: - Acute therapy for an infection or other medical illness within 14 days prior to entry. - Prior protease inhibitor therapy. - Prior NNRTI therapy (approved or experimental). - Erythropoietin, G-CSF or GM-CSF within 30 days prior to entry. - Interferons, interleukins or HIV vaccines within 30 days prior to entry. - Any experimental therapy within 30 days prior to entry. - Rifampin or rifabutin within 14 days prior to entry.
Total Enrollment: 300
Location and Contact Information:
Overall Study Official:
SquiresKE, Study Chair,
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York, 14215
United States
Univ of Washington
Seattle, Washington, 981224304
United States
Great Lakes Hemophilia Foundation
Wauwatosa, Wisconsin, 532130127
United States
Johns Hopkins Hosp
Baltimore, Maryland, 21287
United States
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, 900331079
United States
Indiana Univ Hosp
Indianapolis, Indiana, 462025250
United States
Univ of Colorado Health Sciences Ctr
Denver, Colorado, 80262
United States
St Paul Ramsey Med Ctr
St. Paul, Minnesota, 55101
United States
Ohio State Univ Hosp Clinic
Columbus, Ohio, 432101228
United States
Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr
Knoxville, Tennessee, 37920
United States
Stanford at Kaiser / Kaiser Permanente Med Ctr
San Francisco, California, 94115
United States
Univ of Hawaii
Honolulu, Hawaii, 96816
United States
Beth Israel Deaconess Med Ctr
Boston, Massachusetts, 02215
United States
Louis A Weiss Memorial Hosp
Chicago, Illinois, 60640
United States
Saint Clare's Hosp and Health Ctr
New York City, New York, 10019
United States
Hennepin County Med Clinic
Minneapolis, Minnesota, 55415
United States
Central Prison/Women's Prison in Raleigh / NC
Raleigh, North Carolina, 276260540
United States
Howard Univ
Washington D.C., District of Columbia, 20059
United States
UCLA CARE Ctr
Los Angeles, California, 90095
United States
Georgetown Univ Hosp
Washington D.C., District of Columbia, 20037
United States
Moses H Cone Memorial Hosp
Greensboro, North Carolina, 27401
United States
Beth Israel Med Ctr
New York City, New York, 10003
United States
St Louis Regional Hosp / St Louis Regional Med Ctr
St. Louis, Missouri, 63112
United States
Duke Univ Med Ctr
Durham, North Carolina, 27710
United States
Univ of Minnesota
Minneapolis, Minnesota, 55455
United States
San Francisco Gen Hosp
San Francisco, California, 941102859
United States
Univ of Rochester Medical Center
Rochester, New York, 14642
United States
Cornell Univ Med Ctr
New York City, New York, 10021
United States
Julio Arroyo
West Columbia, South Carolina, 29169
United States
Univ of Puerto Rico
San Juan, , 009365067
Puerto Rico
Tulane Univ School of Medicine
New Orleans, Louisiana, 70112
United States
Milton S Hershey Med Ctr
Hershey, Pennsylvania, 170330850
United States
Univ of Iowa Hosp and Clinic
Iowa City, Iowa, 52242
United States
Beth Israel Deaconess - West Campus
Boston, Massachusetts, 02215
United States
Division of Inf Diseases/ Indiana Univ Hosp
Indianapolis, Indiana, 46202
United States
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr
New York City, New York, 10021
United States
Vanderbilt Univ Med Ctr
Nashville, Tennessee, 37203
United States
Queens Med Ctr
Honolulu, Hawaii, 96816
United States
Univ of Texas Galveston
Galveston, Texas, 775550435
United States
Univ of North Carolina
Chapel Hill, North Carolina, 275997215
United States
Tulane Med Ctr Hosp
New Orleans, Louisiana, 70112
United States
Univ of Nebraska Med Ctr
Omaha, Nebraska, 681985130
United States
State of MD Div of Corrections / Johns Hopkins Univ Hosp
Baltimore, Maryland, 212052196
United States
Univ of Pennsylvania at Philadelphia
Philadelphia, Pennsylvania, 19104
United States
Charity Hosp / Tulane Univ Med School
New Orleans, Louisiana, 70112
United States
Boston Med Ctr
Boston, Massachusetts, 02118
United States
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts, 02114
United States
Northwestern Univ Med School
Chicago, Illinois, 60611
United States
Bellevue Hosp / New York Univ Med Ctr
New York City, New York, 10016
United States
Stanford Univ Med Ctr
Stanford, California, 943055107
United States
Mount Sinai Med Ctr
New York City, New York, 10029
United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612
United States
Univ of Cincinnati
Cincinnati, Ohio, 452670405
United States
Univ of Miami School of Medicine
Miami, Florida, 331361013
United States
Case Western Reserve Univ
Cleveland, Ohio, 44106
United States
Univ of Kentucky Lexington
Cincinnati, Ohio, 45267
United States
Additional Information:
Study ID Numbers: ACTG 368;
Study Start Date:
Record last reviewed: April 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001086
Other Hiv Infections Studies:
1. The Effect of Stomach Acid on Foscarnet
2. A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
3. Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
4. T-20 in HIV Patients with Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
5. Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms
Related Studies:
Other HIV Infections Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients
|
|
|
|
|
|
|
|
